Zoology

MPharm or MSc; Doctorate degree in Life sciences, Biological Sciences/Biochemistry from a recognized University or equivalent

Masters degree in Forensic Science or Botany or Zoology or Micro Biology or Chemistry or Biotechnology or Biochemistry or Genetics or Pharmacology or Pharmacy

MSc. with PhD Biotechnology, Botany, Zoology, Biochemistry, Microbiology Molecularbiology, Genomics, Animal Biotechnology, Tissue Engineering; Candidates with documented experience in Genomics, NGS Data Analysis, Animal Cell Culture, Molecular Biology Techniques.

M.Sc. in Life Sciences, Biotechnology, Biochemistry, Zoology, Molecular Biology, Genetics, Genetic Engineering. Research experience in isolating DNA from blood samples and carrying out PCR. OR Qualified PhD examination of SCTIMST for academic session 2025.

Deciphering the contribution of proestrous-estrous transition to seizure susceptibility in drug resistant epilepsy pathologies. Masters degree in Medical Biophysics, Biochemistry, Zoology, Neuroscience, Biomedical Sciences or any other branch of Life Sciences or M.Pharm Pharmacology.

First class Post Graduate Degree, including the integrated PG degrees in the area of Pharmacology and Toxicology, Life sciences, Biotechnology, Molecular biology, Immunology, Zoology or equivalent with one year of experience.

M.Sc, M.Tech Zoology ,Medical or Human Genetics, Biochemistry, Molecular Biology, Botany, Microbiology, Biotechnology, Life Sciences, Applied Biology, Cytogenetics. Candidates should have minimum six months experience in Cytogenetics

Master Degree in Botany or Zoology or Microbiology or Biotechnology or Biochemistry or Physical Anthropology or Genetics or Forensic Science with Botany or Zoology as one of the subjects during all the three years of bachelor of Science from a recognised University or Institute.

Dr. B. Borooah Cancer Institute, Guwahati is hiring following staff on contractual basis for Dr Reddy’s Laboratories supported trial A phase 4. multicenter, non-comparative, open-iabel. two cohort study evaluating the safety and efficacy of intravenously administered toripalimab in the treatment of Indian patients with recurrent or metastatic nasopharyngeal carcinoma.